{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:27:22Z","timestamp":1790008042418,"version":"4.0.1"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamaoncol.2018.0170","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T12:54:13Z","timestamp":1523019253000},"page":"857","source":"Crossref","is-referenced-by-count":29,"title":["Management of Metastatic Melanoma in 2018"],"prefix":"10.1001","volume":"4","author":[{"given":"Howard L.","family":"Kaufman","sequence":"first","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Margolin","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"cit180001r1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.seminoncol.2015.02.010","article-title":"Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.","volume":"42","author":"Eggermont","year":"2015","journal-title":"Semin Oncol"},{"issue":"1","key":"cit180001r2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"cit180001r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma.","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"cit180001r4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00262-016-1910-x","article-title":"Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.","volume":"65","author":"Alva","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"cit180001r5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies.","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2677295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T12:32:08Z","timestamp":1528979528000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.0170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.0170","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}